2017 ESC/EACTS Guidelines for the management of valvular heart disease

Abstract

The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to Oxford University Press, the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oxfordjournals.org).Disclaimer. The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time of their publication. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient's health condition and in consultation with that patient and, where appropriate and/or necessary, the patient's caregiver. Nor do the ESC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities in order to manage each patient s case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional's responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.The article has been co-published with permission in the European Heart Journal [10.1093/eurheartj/ehx391] on behalf of the European Society of Cardiology and European Journal of Cardio-Thoracic Surgery [10.1093/ejcts/ezx324] on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved in respect of European Heart Journal, V C European Society of Cardiology 2017. The articles are identical except for minor stylistic and spelling differences in keeping with each journal's style. Either citation can be used when citing this article.

Multiscale simulation of the effects of atrioventricular block and valve diseases on heart performance

“…Mean pressure gradients and peak flow velocity obtained from numerical simulations are shown; values in brackets correspond to the boundaries for ranges of the stenosis severity presented in Guidelines …”

Analyses for Prevalence and Outcome of Tricuspid Regurgitation in China: An Echocardiography Study of 134,874 Patients

“…However, the major clinical diagnoses of the patients could also be collected in the echocardiography database at our center and were rechecked by the echocardiography reports. Forth, the recent ESC/EACTS guidelines [29] stress the importance of tricuspid disease especially in patients with significant mitral valve disease, and the time for intervention of TR should be considered early. Our research found that severe TR patients with left-sided valve surgery have a better prognosis than those who did not accept left-sided valve surgery, which demonstrates the benefits of left-sided valve intervention.…”

Transcatheter aortic valve implantation in low-risk patients: is it too early?

“…This is already reflected in the 2017 ESC/EACTS Valvular Heart Disease Guidelines in which age >75 alone is considered in the list of factors favouring TAVI if transfemoral access is possible 39. However, in patients with greater life expectancy, TAVI durability is still an unanswered question requiring further follow-up.…”